



NORTH-WEST UNIVERSITY
YUNIBESITI YA BOKONE-BOPHIRIMA
NOORDWES-UNIVERSITEIT
POTCHEFSTROOMKAMPUS

A metabolomics approach for characterising tuberculosis

Ilse Olivier

**Thesis submitted for the degree Philosophiae Doctor in Biochemistry at the
Centre for Human Metabonomics, School for Physical and Chemical Sciences,
North-West University, Potchefstroom campus**

Promotor: Prof. Du Toit Loots

May 2012

Potchefstroom

Education is not the filling of a bucket, but the lighting of a fire.
~ W.B. Yeats ~

TABLE OF CONTENTS

Acknowledgements -----	i
Summary -----	ii
Key words -----	iii
Opsomming -----	iv
Sleuteltermen -----	vi
List of tables -----	vii
List of figures -----	ix
List of abbreviations -----	xiii

CHAPTER 1: Preface

1. Background and motivation -----	2
2. Aims and objectives of the study -----	4
2.1 Aim -----	4
2.2 Objectives -----	4
3. Structure of thesis -----	4
4. Outcomes of the study -----	6
4.1 Manuscripts -----	6
4.2 Registered preliminary patent -----	7
5. Authors contributions -----	8
6. References -----	9

CHAPTER 2: Introduction

1. Introduction -----	12
2. Pathophysiology of tuberculosis -----	12
3. Tuberculosis vaccination -----	13
4. Tuberculosis treatment -----	14
4.1 First-line medications -----	15
4.1.1 Streptomycin -----	15
4.1.2 Isoniazid -----	16
4.1.3 Ethambutol -----	18
4.1.4 Rifampicin -----	18
4.1.5 Pyrazinamide -----	19
4.2 Second-line medication -----	20

4.2.1 D-Cycloserine	20
4.2.2 Ethionamide	21
4.2.3 Kanamycin and amikacin	21
4.2.4 Fluoroquinolones	22
5. Tuberculosis diagnostics	25
5.1 Tuberculin skin test	25
5.2 Cytokine detection assay	26
5.3 Radiographic methods	26
5.4 Microscopic examination	27
5.5 Bacteriological culture	28
5.6 High performance liquid chromatography	30
5.7 Nucleic acid amplification	30
5.8 Serology	31
5.9 Phage assay	32
6. The role of metabolomics in TB research	32
7. Conclusion.....	35
8. References	36

CHAPTER 3: A fatty acid metabolomics approach to differentiate and characterise various *Mycobacterium* species

1. Introduction	48
2. Materials and methods	49
2.1 Reagents and chemicals	49
2.2 Sample collection and preparation	49
2.3 Extraction procedures	50
2.4 GC-MS parameters	51
2.5 Data-acquisition	52
2.6 Statistical data analysis	52
3. Results and discussion	54
3.1 Comparative repeatability and extraction capacity of the three fatty acid extraction procedures	54
3.2 Bacterial fatty acid content	55
3.3 Differentiation capacity	57
3.4 Detection limit	60
4. Conclusions	61
5. References	62

CHAPTER 4: The effect of rifampicin-resistance conferring mutations on the fatty acid metabolome of *M. tuberculosis*

1. Introduction -----	65
2. Materials and methods -----	66
2.1 Reagents and chemicals -----	66
2.2 Bacterial cultures -----	66
2.3 Extraction procedure -----	67
2.4 GC-MS analysis and data processing -----	67
2.5 Statistical data analysis -----	67
3. Results -----	68
3.1 Differentiation between wild-type and rifampicin-resistant strains -----	68
3.2 Identification of potential biomarkers characteristic of specific rifampicin-resistant conferring <i>rpoB</i> mutations -----	69
4. Discussion -----	71
5. Conclusions -----	75
6. References -----	76

CHAPTER 5: Further development and comparison of a simpler fatty acid and total metabolome extraction procedure for differentiating various *Mycobacterium* species and *P. aeruginosa*

1. Introduction -----	80
2. Materials and methods -----	81
2.1 Reagents and chemicals -----	81
2.2 Bacterial cultures -----	81
2.3 Extraction procedure 1 – Fatty acid metabolome extraction -----	82
2.4 Extraction procedure 2 - Total metabolome extraction -----	82
2.5 GC-MS parameters -----	82
2.6 Data-acquisition -----	83
2.7 Statistical data analysis -----	83
3. Results and discussion -----	84
3.1 Extraction capacity -----	84
3.2 Repeatability -----	85
3.3 Comparison of each extraction method's capacity for metabolomics species differentiation -----	86

3.4 Detection limits -----	88
3.5 Metabolite marker identification -----	91
4. Conclusions -----	95
5. References -----	95

CHAPTER 6: A comparison of four different sputum pre-extraction preparations methods, prior to GCxGC-TOFMS metabolomics analysis, to characterise *M. tuberculosis* from patient collected sputum

1. Introduction -----	98
2. Materials and methods -----	99
2.1 Reagents and chemicals -----	99
2.2 Sputum samples -----	99
2.3 Bacterial cultures -----	100
2.4 Sputum pre-extraction preparation methods -----	100
2.4.1 NaOH sputum pre-extraction preparation method -----	100
2.4.2 Sputolysin sputum pre-extraction preparation method -----	101
2.4.3 NaOH-NALC sputum pre-extraction preparation method -----	101
2.4.4 Ethanol homogenisation -----	101
2.5 Extraction procedure -----	102
2.6 GCxGC-TOFMS parameters -----	102
2.7 Peak identification and alignment -----	103
2.8 Statistical data analysis -----	103
3. Results and discussion -----	104
3.1 Repeatability -----	104
3.2 Extraction efficiency -----	107
3.3 Capacity to extract those compounds differentiating the investigated sample groups -----	108
3.4 Metabolite marker identification -----	110
3.5 Detection limits and minimum sample volumes required -----	115
4. Conclusions -----	117
5. References -----	118

CHAPTER 7: Characterising TB using patient collected sputum and GCxGC-TOFMS metabolomics

1. Introduction -----	121
2. Materials and methods -----	122

2.1 Reagents and chemicals -----	122
2.2 Sputum samples -----	122
2.3 Extraction procedure -----	122
2.4 GCxGC-TOFMS parameters -----	123
2.5 Peak identification and alignment -----	123
2.6 Statistical data analysis -----	123
3. Results and discussion -----	124
3.1 Differentiation of the patient collected TB-positive and TB-negative sputum samples on the basis of their detected metabolite differences -----	124
3.2 Potential TB metabolite markers -----	128
4. Conclusions -----	134
5. References -----	135

CHAPTER 8: Discussion and conclusions

1. Introduction -----	139
2. Summary of the main findings -----	139
3. Final remarks and future recommendations -----	142

APPENDIX A - Manuscripts

1. OLIVIER I., LOOTS, D.T. 2011. An overview of tuberculosis treatments and diagnostics. What role could metabolomics play? *J. Cell Tissue Res.* 11(1): 2655-2671
2. OLIVIER, I., LOOTS, D.T. 2012. A metabolomics approach to characterise and identify various *Mycobacterium* species. *J. Microbiol. Meth.* 88: 419-426
3. OLIVIER, I., LOOTS, D.T. Altered fatty acid metabolism due to rifampicin-resistance conferring mutations in the *rpoB* gene of *M. tuberculosis*. *OMICS*. Submitted. Manuscript nr. OMI-2012-0028
4. OLIVIER, I., LOOTS, D.T. 2012. A comparison of two extraction methods for differentiating and characterising various *Mycobacterium* species and *Pseudomonas aeruginosa* using GC-MS metabolomics. *Afr. J. Microbiol. Res.* 6(13): 3159-3172

APPENDIX B - Registered preliminary patent

LOOTS, D.T., OLIVIER, I. 2011. Method of distinguishing between different pathogens. Patent: ZA, 2011/03029. 54 p.

ACKNOWLEDGEMENTS

The contributions of the following institutions and individuals made towards the successful completion of this study are hereby acknowledged:

The Royal Tropical Institute (KIT), Amsterdam, The Netherlands for providing access to all the bacterial samples used, Hans de Ronde for performing bacterial culture, and Dr. Richard Anthony and Prof. Paul Klatser for useful discussions.

AMPATH laboratories, Pretoria, South Africa (especially Dr. Jennifer Coetzee and Eileen Grabowski), for providing the patient collected sputum samples used in this investigation.

Dr. Gerhard Koekemoer (Statistical Consultation Services, North-West University, Potchefstroom, South Africa) for his guidance with regards to the statistical data analyses.

The National Research Foundation (NRF) of South Africa, the Technology Innovation Agency (TIA) and the North-West University (NWU) for the research grants provided.

Mr. Peet Jansen van Rensburg for assistance with the analytical equipment used.

Prof. Du Toit Loots, my study supervisor, the other members of the NWU Infectious Disease Metabolomics Laboratory (including Enrike Weyers, Reinart Meissner-Roloff, and Nelus Schoeman), and all the other students and staff members of the Centre for Human Metabonomics, for sharing their expertise and friendship with me during this time.

My parents, Hein and Thelma, for their ongoing physical, emotional and financial support during the course of this Ph.D. study.

My fiancé, Dupi, for all your love, patience and support.

SUMMARY

In 2001, the WHO declared tuberculosis (TB) a global emergency, as one third of the world's population suffered from latent *M. tuberculosis* infection. Today, a decade later, millions of people still die worldwide as a result of this disease. This growing TB incidence may be ascribed to a variety of reasons, including, amongst others, the inadequacies associated with the currently available diagnostic methods and TB treatment regimes, especially when considering the growing MDR-TB and HIV epidemics.

This study investigated the potential of metabolomics as a tool for characterising TB and various TB-causing bacteria, allowing for a better understanding of TB disease mechanisms, which may ultimately lead to improved diagnostic and treatment regimens.

Firstly, we investigated the potential of a fatty acid, metabolomics approach to characterise various cultured *Mycobacterium* species. For this exploration, three fatty acid extraction procedures, prior to GC-MS analyses, were compared based on their respective repeatability and extraction capacities. Using the data obtained from the analyses done with the most optimal extraction approach (the modified Bligh-Dyer method), multivariate statistical analyses were able to differentiate between the various *Mycobacterium* species at a detection limit of 1×10^3 bacterial mL^{-1} , in 16 hours. Subsequently, the compounds best describing the variation between the sample groups were identified as potential metabolite markers and were discussed in the light of previous studies.

The most optimal GC-MS, fatty acid metabolomics approach, mentioned above, was then applied to analyse and characterise a wild-type *M. tuberculosis* parent strain and two rifampicin-resistant conferring *rpoB* mutants (S522L and S531L). Due to the variation in their fatty acid profiles, a clear differentiation was achieved between these *M. tuberculosis* sample groups, and those metabolites contributing most to this variation were identified as metabolite markers characteristic for rifampicin-resistance. The altered metabolite markers detected in the *rpoB* mutants propose a decreased synthesis of various 10-methyl branched-chain fatty acids and cell wall lipids, and an increased use of the shorter-chain fatty acids and alkanes as alternative carbon sources. Furthermore, the *rpoB* S531L mutant, previously reported to occur in well over 50% of all clinical rifampicin-resistant *M. tuberculosis* strains, showed a better capacity for using these alternative energy sources, in comparison to the less frequently detected *rpoB* S522L mutant.

The developed fatty acid GC-MS metabolomics approach was then successfully adapted in order to improve its speed, cost and complexity. This improved fatty acid extraction method

was furthermore compared to another, similar approach (total metabolome extraction method), developed for the extraction of a much wider variety of compounds, prior to GC-MS and statistical data analyses. Although both these methods show promise for bacterial characterisation using metabolomics, the total metabolome extraction method proved the better of the two methods because it is comparatively simpler, faster (taking less than 4 hours), more repeatable, better differentiates between sample groups due to less within group variation, has a lower detection limit, and isolates a wider variety of biologically relevant metabolites (as opposed to fatty acids alone). We, furthermore, identified and described the occurrence of those compounds, extracted by both methods, which contribute most to the variation between the bacterial groups, in order to validate these methods for metabolomic applications and the isolation of compounds with biological relevance.

In order to evaluate the potential of this developed metabolomics approach for application to biological samples other than bacteriological cultures, it was adapted for the direct analyses of complex sputum samples. For this application, four sputum pre-extraction preparation methods, including three standard *Mycobacterium* cell isolation procedures (Sputolysin, NALC-NaOH, and NaOH) and a fourth, applying only a simple ethanol homogenisation step, prior to direct sputum extraction, were compared. Of these methods, the ethanol homogenisation method proved to have the best comparative extraction efficiency, repeatability and differentiation capacity, when used in combination with the previously developed metabolomics methods. Subsequently, when applying this approach to patient collected sputum samples, a set of metabolite markers, differentiating the TB-positive from the TB-negative samples, were identified. These markers could directly be linked to: 1) the physical presence of the *M. tuberculosis* in these samples; 2) changes in the bacterial metabolome due to *in vivo* growth conditions and; 3) changes in the human metabolome due to pulmonary *M. tuberculosis* infection.

In addition to the proposal of a number of new hypotheses, explaining various mechanisms of TB and drug-resistant TB, the mapping of the newly identified metabolite markers to known metabolic pathways led to the confirmation of various previously suggested metabolic pathways and alterations thereof due to an assortment of perturbations. Therefore, this study significantly contributes to the characterisation of various TB causing bacteria, rifampicin-resistant *M. tuberculosis* strains and the TB disease state, which may in future lead to the development of innovative TB vaccination, diagnostic and treatment protocols.

Key words: Metabolomics; *Mycobacterium*; Rifampicin-resistance; Tuberculosis.

OPSOMMING

AFRIKAANSE TITEL:

'n Metabolomika benadering om tuberkulose te karakteriseer

In 2001 het die Wêreld Gesondheid Organisasie tuberkulose (TB) as 'n globale noodtoestand verklaar aangesien een derde van die wêreld se bevolking aan latente *M. tuberculosis* infeksie gely het. Vandag, 'n dekadde later, sterf miljoene mense steeds wêreldwyd as gevolg van hierdie siekte. Hierdie groeiende voorkoms van TB kan toegeskryf word aan 'n verskeidenheid van redes wat onder andere die oneffektiwiteit van die huidige beskikbare diagnostiese metodes en TB-behandelings regimes, veral wanneer die groeiende voorkoms van medisyne weerstandbiedende TB en MIV-epidemies in ag geneem word, insluit.

Hierdie studie het die potensiaal van metabolomika vir die karakterisering van TB en verskeie TB veroorsakende bakterieë, om sodoende 'n beter begrip van TB meganismes te bekom, ondersoek. Hierdie karakterisering kan uiteindelik lei tot die ontwikkeling van beter diagnostiese en behandeling regimes.

Eerstens het ons die potensiaal van 'n vetsuur, metabolomika benadering ondersoek om verskillende gekweekte *Mycobacterium* spesies te karakteriseer. Vir hierdie verkenning is drie vetsuur ekstraksie prosedures, voor GC-MS analisering, vergelyk op grond van hul onderskeie herhaalbaarheid en ekstraksie vermoëns. Deur gebruik te maak van die GC-MS data verkry na die analisering van die bakteriële ekstrakte, vanaf die mees optimale ekstraksie benadering (die gewysigde Blich-Dyer metode), kon ons onderskeid tref tussen die verskillende *Mycobacterium* spesies by 'n deteksie limiet van 1×10^3 bakterie mL^{-1} , in 16 ure. Vervolgens is die verbindings wat die variasie tussen die groepe die beste beskryf geïdentifiseer as potensiële metaboliet merkers en bespreek in die lig van vorige studies.

Die bogenoemde, mees optimale GC-MS, vetsuur metabolomika benadering, was daarna aangewend om 'n wilde-tipe *M. tuberculosis* oer en twee rifampisien-weerstandbiedende *rpoB* mutante (S522L en S531L) te ontleed en te karakteriseer. As gevolg van die variasie in hul vetsuur profiele kon 'n duidelike onderskeid getref word tussen hierdie *M. tuberculosis* monster groepe, en die metaboliete wat die meeste bydra tot hierdie variasie is geïdentifiseer as metaboliet merkers wat kenmerkend is vir rifampisien-weerstandbiedendheid. Die metaboliet merkers wat geïdentifiseer was vir die *rpoB* mutante dui op 'n afname in die sintese van verskeie 10-metiel vertakte ketting vetsure en selwand lipiede, en 'n toename in die gebruik van die korter ketting vetsure en alkane as alternatiewe koolstof bronne. Verder was dit

waargeneem dat die *rpoB* S531L mutant, voorheen gerapporteer om voor te kom in meer as 50% van alle kliniese rifampisien-weerstandbiedende *M. tuberculosis* monsters, 'n beter kapasiteit het om hierdie alternatiewe energiebronne te gebruik, in vergelyking met die *rpoB* S522L mutant, wat minder klinies voorkom.

Die ontwikkelde vetsuur GC-MS metabolomika benadering is hierna suksesvol aangepas om sy spoed, koste en kompleksiteit te verbeter. Hierdie verbeterde vetsuur ekstraksie metode is verder vergelyk met 'n ander, soortgelyke benadering (totale metaboloom ekstraksie metode), wat ontwikkel is om 'n veel wyer verskeidenheid van verbindings te ekstraheer, voor GC-MS en statistiese data ontleding. Alhoewel albei hierdie metodes beloofde resultate getoon het vir bakteriële karakterisering met behulp van metabolomika, het die totale metaboloom ekstraksie metode beter gevaar, want dit: 1) is relatief makliker, 2) is vinniger (neem minder as 4 ure), 3) is meer herhaalbaar en onderskei dus beter tussen die bakteriële monster groepe as gevolg van minder binne groep variasie 4) het 'n laer deteksie limiet en 5) isoleer 'n groter verskeidenheid van biologies relevante metaboliete (in teenstelling met vetsure alleen). Ons het voorts die metaboliete wat die meeste bydra tot die variasie tussen die bakteriële groepe, geëkstraheer deur beide metodes, geïdentifiseer en die voorkoms van hierdie verbindings bespreek, om sodoende hierdie metodes te evalueer vir metabolomika toepassings en hul vermoë om biologiese relevante verbindings te isoleer.

Om ten einde die potensiaal van hierdie ontwikkelde metabolomika benadering te evalueer vir toepassing op ander biologiese monsters as bakteriologiese kulture, is dit aangepas vir die direkte ontleding van komplekse sputum monsters. Vir hierdie aanpassing is vier sputum pre-ekstraksie voorbereiding metodes, insluitende drie standaard *Mycobacterium* sel isolasie prosedures (Sputolysin, NALC-NaOH, en NaOH) en 'n vierde, 'n eenvoudige etanol homogenisasie stap, voor sputum ekstraksie, vergelyk. Tussen hierdie metodes het die etanol homogenisasie metode die beste vergelykende ekstraksie doeltreffendheid, herhaalbaarheid en differensiasie kapasiteit getoon wanneer dit gebruik was in kombinasie met die voorheen ontwikkelde metabolomika metodes. Daarna is hierdie benadering toegepas op pasiënt versamelde sputum monsters om 'n stel metaboliet merkers, wat die meeste verskil tussen die TB-positiewe van die TB-negatiewe monsters, te identifiseer. Hierdie merkers kon direk gekoppel word aan: 1) die fisiese teenwoordigheid van *M. tuberculosis* in hierdie monsters; 2) veranderinge in die bakteriële metaboloom as gevolg van *in vivo* groei toestand en 3) die veranderinge in die menslike metaboloom as gevolg van pulmonêre *M. tuberculosis* infeksie.

Benewens die voorstel van 'n aantal nuwe hipoteses, wat verskeie meganismes van TB en medisyne weerstandbiedende TB verklaar, het die karakterisering van die nuut geïdentifiseerde metaboliet merkers gelei tot die bevestiging van verskeie voorheen voorgestelde metaboliese

bane en wysigings van bekende metaboliese bane as gevolg van 'n verskeidenheid van eksterne faktore. Daarom dra hierdie studie betekenisvol by tot die karakterisering van verskeie TB veroorsaak bakterieë, rifampisien-weerstandbiedende *M. tuberculosis* en die TB siekte toestand, wat dalk in die toekoms kan lei tot die ontwikkeling van innoverende TB inenting-, diagnostiese- en behandelingsprotokolle.

Sleuteltermes: Metabolomika; *Mycobacterium*; Rifampisien-weerstandbiedendheid; Tuberkulose.

LIST OF TABLES

Chapter 1

Table 1.1: Research Team	9
---------------------------------------	---

Chapter 2

Table 2.1: Mode of action of commonly used anti-TB drugs.	24
-----------------------------------------------------------------------	----

Chapter 3

Table 3.1: Mean relative concentrations of the most abundant fatty acids detected in the four <i>Mycobacterium</i> species, extracted using the modified Bligh-Dyer approach. Standard deviations are given in parenthesis.	56
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----

Table 3.2: Mean relative concentrations of the metabolite markers identified for the various <i>Mycobacterium</i> species. Standard deviations are given in parenthesis.	58
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----

Chapter 4

Table 4.1: Mean relative concentrations and rankings of metabolite markers, as identified by PCA and PLS-DA. Standard deviations are given in parenthesis.	70
------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----

Chapter 5

Table 5.1: Number of compounds in the AMDIS generated reference libraries, originating from each of the bacterial sample groups, for the two investigated extraction methods. The standard deviations, representing the variation in the number of compounds detected between individual samples, are given in parenthesis.	85
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----

Table 5.2: Mean relative concentrations ($\mu\text{g mg}^{-1}$ sample) of the metabolite markers identified for the various infectious organism groups using the fatty acid metabolome extraction procedure. Standard deviations are given in parenthesis.	92
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----

Table 5.3: Mean relative concentrations ($\mu\text{g mg}^{-1}$ sample) of the metabolite markers identified for the various infectious organism groups investigated using the total metabolome extraction procedure. Standard deviations are given in parenthesis. ----- 94

Chapter 6

Table 6.1: Comparative calculations including: coefficients of variation (CV) values, number of compounds detected and number of sample outliers identified, for the four sputum pre-extraction preparation methods. ----- 107

Table 6.2: The top 20 ranked VIPs identified via PLS-DA, using the data obtained after NALC-NaOH sputum preparation, extraction and GCxGC-TOFMS analysis of the control and *M. tuberculosis* spiked sputum samples. ----- 111

Table 6.3: The top 20 ranked VIPs identified via PLS-DA, using the data obtained after ethanol homogenisation, extraction and GCxGC-TOFMS analysis of the control and *M. tuberculosis* spiked sputum samples. ----- 113

Chapter 7

Table 7.1: Metabolite markers best describing the variation between TB-positive and TB-negative sputum samples. ----- 129

LIST OF FIGURES

Chapter 3

Figure 3.1: Distribution of the coefficient of variation (CV) values of all the compounds detected through GC-MS analyses of the *M. tuberculosis* sample repeats after extraction via each of the three compared extraction procedures. The best repeatability was obtained using the modified Bligh-Dyer extraction method. ----- 55

Figure 3.2: Three-dimensional PCA scores plot of the GC-MS generated metabolite data after extraction of the bacterial samples using the modified Bligh-Dyer method, showing a clear differentiation between the four *Mycobacterium* sample groups at a concentration of 1×10^8 bacteria mL^{-1} . ----- 57

Figure 3.3: Probabilities for the “unknown” test samples (2 for each group) correctly identified for: *M. tuberculosis* are 100% in both cases; for *M. kansasii*: 92% and 91%; for *M. bovis*: 97% and 72%; and for *M. avium*: 97% and 93%. (o = original samples used to build the model, x = “unknown” test samples) ----- 59

Figure 3.4: Three-dimensional PCA scores plot of the GC-MS generated data (after extraction using the modified Bligh-Dyer method) of the various prepared *M. tuberculosis* dilutions. All the groups, except that containing 1×10^2 bacteria mL^{-1} , could be distinguished from the blank group, determining a potential detection limit of 1×10^3 bacteria mL^{-1} . ----- 60

Figure 3.5: Three-dimensional PCA scores plot of the GC-MS generated data after extraction of the four *Mycobacterium* sample repeats using the modified Bligh-Dyer method, showing a clear differentiation between *Mycobacterium* sample groups at a concentration of 1×10^3 bacteria mL^{-1} . ----- 61

Chapter 4

Figure 4.1: PCA scores plot showing PC 1 vs. PC 2 of the *M. tuberculosis* wild-type parent strain and the two rifampicin-resistant conferring *rpoB* mutants (12 individually cultures sample isolates for each strain), subsequent to fatty acid extraction and GC-MS analyses, indicating a differentiation of the three *M. tuberculosis* strains. ----- 68

Figure 4.2: The role of the *rpoB* gene in the biosynthesis of 10-methyl-branched fatty acids in *M. tuberculosis*. FAS I and FAS II generate fatty acyl-CoA esters from acetyl-CoA, which are dehydrogenated to their corresponding Δ^9 -mono-unsaturated straight-chain fatty acids, and ultimately methylated to form 10-methyl branched fatty acids, with S-adenosylmethionine acting as the methyl donor. The dehydrogenation step requires Fe^{2+} , GTP derived FMN, NADPH and O_2 . The availability of GTP for this process is dependent on its equilibrium with mRNA, regulated by phosphoribosyltransferase and RNA polymerase (*rpoB* expression). ----- 72

Chapter 5

Figure 5.1: Distribution of the calculated coefficient of variation (CV) values for all the GC-MS detected compounds from each infectious organism group (12 sample repeats of each organism), extracted using the two extraction methods comparatively investigated. ----- 86

Figure 5.2: PCA scores plot (PC1 vs. PC3) of the GC-MS data acquired using the fatty acid metabolome extraction, indicating a grouping of the individual samples into their respective organism groups on the basis of the variation in the detected fatty acid metabolomes. ----- 87

Figure 5.3: PCA scores plot (PC1 vs. PC3) of the GC-MS data acquired using the total metabolome extraction, indicating a grouping of the individual samples into their respective organism groups, with a comparatively smaller within group variation, and hence, bigger inter-group variation, compared to that of the fatty acid extraction procedure. ----- 88

Figure 5.4: PCA scores plot (PC 1 vs. PC 2 vs. PC 3) of the GC-MS generated data of the concentration gradient samples of *M. tuberculosis* using the fatty acid metabolome extraction method. The lowest bacterial concentration not overlapping with the blank, and hence the detection limit for this method, is 1×10^4 bacteria mL^{-1} . ----- 89

Figure 5.5: PCA scores plot (PC 1 vs. PC 2 vs. PC 3) of the GC-MS generated data of the concentration gradient samples of *M. tuberculosis* using the total metabolome extraction method. The lowest bacterial concentration not overlapping with the blank, and hence the detection limit for this method, is 1×10^3 bacteria mL^{-1} . ----- 90

Figure 5.6: Three-dimensional PCA scores plot of the GC-MS generated data after extraction of the five bacterial sample repeats, showing a clear differentiation between all the sample groups at a concentration of 1×10^4 bacteria mL^{-1} using the fatty acid extraction method and 1×10^3 bacteria mL^{-1} using the total metabolome extraction method. ----- 91

Chapter 6

Figure 6.1: Distribution of the coefficients of variation (CV) values of the relative concentrations of all the compounds detected in the control and *M. tuberculosis* spiked sputum samples subsequent to sputum pre-extraction preparation using one of the four investigated methods, followed by extraction and GC x GC-TOFMS analysis. ----- 105

Figure 6.2: PCA scores plots showing the differentiation between the pooled control and pooled spiked sputum sample repeats using the GCxGC-TOFMS generated data of the analysed extracts obtained via the four sputum preparation methods. In each case, three PCs were extracted. The cumulative variance explained in the data by each PC is indicated in parenthesis. ----- 109

Figure 6.3: PCA scores plot (PC 1 vs. PC 2 vs. PC 3) showing the concentration gradient analysis of the *M. tuberculosis* spiked sputum, comparing the (a) NALC-NaOH and (b) ethanol homogenisation sputum pre-extraction preparation methods. The lowest bacterial concentration not overlapping with the control was considered the detection limit or minimum amount of *M. tuberculosis* required to be present in a sputum sample for extraction and GCxGC-TOFMS analysis of the characteristic metabolites required for differentiation of TB-positive and TB-negative sputa, using this metabolomics research approach. ----- 116

Chapter 7

Figure 7.1: PCA scores plots of the GCxGC-TOFMS generated data, showing TB-negative (N) vs. TB-positive (T) patient collected sputum samples before the removal of 'noise' and interfering compounds from the dataset. ----- 125

Figure 7.2: Statistical approach used for metabolite "noise" reduction and removal of outlier samples, in order to identify metabolite markers best explaining the variation between TB-positive and TB-negative sputum samples. ----- 126

Figure 7.3: PCA scoresplots of the GCxGC-TOFMS generated data, showing TB-negative (N) vs. TB-positive (T) patient collected sputum samples after the removal of 'noise' compounds from the dataset. ----- 127

Figure 7.4: Schematic representation of the interaction between the glyoxylate, citramalate and Krebs cycles of *M. tuberculosis*. During pulmonary infection, both fatty acid oxidation and the glyoxylate cycle are up regulated in *M. tuberculosis*, leading to increased citramalic acid, through the up-regulated citramalate cycle, and GABA for the purpose of fuelling the up-regulated glyoxylate cycle. ----- 130

Figure 7.5: Proposed changes to the metabolism of the human host due to pulmonary *M. tuberculosis* infection. This diagram indicates elevated concentrations of various metabolites (those in bold), as a result of an increased production of H₂O₂ via glucose oxidation and direct synthesis from the infected macrophage, as a defence mechanism, resulting in increased oxidative stress and lipid peroxidation. ----- 132

LIST OF ABBREVIATIONS

AIDS	acquired immunodeficiency syndrome
Alr	D-alanine racemase
AMDIS	automated mass spectral deconvolution and identification system
ATD/GC-MS	automated thermal desorption, gas chromatography and mass spectroscopy
ATP	adenosine triphosphate
BCG	bacille Calmette-Guerin
CDA	canonical discriminant analysis
CF	cystic fibroses
CFP	culture filtrate protein
CFU	colony forming unit
CoA	coenzyme-A
CTP	cytidine triphosphate
CV	coefficient of variance
CXR	chest X-rays
Ddl	D-alanine:D-alanine ligase
DNA	deoxyribonucleic acid
DOTS	directly observed treatment, short-course
DST	drug susceptibility testing
E-MTD	enhanced <i>Mycobacterium tuberculosis</i> direct
ESAT	early secreted antigen target
FAD	flavin adenine dinucleotide
FAS	fatty acid synthase
FMN	flavin mononucleotide
GABA	γ -aminobutyric acid
GC-MS	gas chromatography mass spectrometry
GCxGC-TOFMS	two-dimensional gas chromatography time of flight mass spectroscopy
GidB	7-methylguanosine methyltransferase
GTP	guanosine triphosphate
HCl	hydrochloric acid
HIV	human immunodeficiency virus
HPLC	high performance liquid chromatography
IGRA	INF- γ release assay
INF- γ	interferon-gamma
KOH	potassium hydroxide
LAM	lipoarabinomannan
MADD	multiple acyl-CoA dehydrogenase defect
MACP	mycolic acid cleavage product
mAG	mycolylarabinogalactan
MDG	millennium development goal

MDR	multidrug-resistant
MGIT	mycobacterial growth indicator tube
MODS	microscopic observation drug susceptibility
MSTFA	N-methy-N-(trimethylsilyl) trifluoroacetamide
MTBSTFA	N-methyl-N-(tert-butyldimethylsilyl) trifluoroacetamide
NaOH	sodium hydroxide
NAD	nicotinamide adenine dinucleotide
NADP	nicotinamide adenine dinucleotide phosphate
NALC	N-acetyl-L-cysteine
NAT	nucleic acid amplification test
NTB	non-tuberculosis
PBS	phosphate buffered saline
PC	principal component
PCA	principal component analysis
PCR	polymerase chain reaction
PLS-DA	partial least squares discriminant analysis
POA	pyrazinoic acid
PPD	purified protein derivative
PZase	pyrazinamidase
RD	regions of difference
RFLP	restriction fragment length polymorphism
RNA	ribonucleic acid
ROS	reactive oxygen species
RRDR	rifampicin-resistance determining region
SAM	S-adenosylmethionine
SDA	strand displacement amplification
SV	similarity value
TB	tuberculosis
TBSA	tuberculostearic acid
TMA	transcription mediated amplification
TMCS	trimethylchlorosilane
TST	tuberculin skin test
UTP	uridine triphosphate
VIP	variable influence on the projection volatile organic compound
VOC	volatile organic compound
WHO	World Health Organization